Pacer Advisors Inc. bought a new stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 20,333 shares of the company’s stock, valued at approximately $1,307,000.
A number of other hedge funds have also recently added to or reduced their stakes in the business. FMR LLC increased its holdings in Ionis Pharmaceuticals by 0.6% in the 1st quarter. FMR LLC now owns 20,633,698 shares of the company’s stock valued at $1,674,837,000 after buying an additional 123,948 shares during the period. First Trust Advisors LP boosted its position in Ionis Pharmaceuticals by 16.7% during the 1st quarter. First Trust Advisors LP now owns 2,591,839 shares of the company’s stock worth $210,380,000 after buying an additional 370,977 shares during the period. OppenheimerFunds Inc. boosted its position in Ionis Pharmaceuticals by 0.4% during the 1st quarter. OppenheimerFunds Inc. now owns 2,027,449 shares of the company’s stock worth $164,568,000 after buying an additional 7,323 shares during the period. Renaissance Technologies LLC acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $112,814,000. Finally, Geode Capital Management LLC boosted its position in Ionis Pharmaceuticals by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 1,341,433 shares of the company’s stock worth $72,517,000 after buying an additional 82,152 shares during the period. 90.54% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have issued reports on IONS. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. ValuEngine lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Piper Jaffray Companies set a $75.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, May 24th. TheStreet lowered shares of Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, August 8th. Finally, Evercore ISI set a $76.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. Ionis Pharmaceuticals has an average rating of “Hold” and an average target price of $69.00.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.26. The company had revenue of $164.00 million during the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. Ionis Pharmaceuticals’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) EPS. Research analysts expect that Ionis Pharmaceuticals Inc will post -0.07 earnings per share for the current fiscal year.
In other Ionis Pharmaceuticals news, CEO Stanley T. Crooke sold 10,000 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $70.25, for a total transaction of $702,500.00. Following the completion of the sale, the chief executive officer now owns 79,634 shares in the company, valued at approximately $5,594,288.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Stanley T. Crooke sold 22,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $71.52, for a total transaction of $1,573,440.00. Following the sale, the chairman now owns 79,634 shares of the company’s stock, valued at approximately $5,695,423.68. The disclosure for this sale can be found here. Insiders sold a total of 47,210 shares of company stock valued at $3,244,934 in the last quarter. 2.40% of the stock is currently owned by company insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
See Also: What is a Tariff?
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.